in vivo News and Research

RSS

Pharnext closes €4.8-million Series A funding round

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it had closed a €4.8-million Series A round of funding on June 3rd (corresponding to a company valuation of €45 million).

9 Jun 2010

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.

8 Jun 2010

New technology involving adipose stem cells may one day cure patients with severe wounds: Researchers

New technology developed by University of Virginia inventors involving adipose stem cells - adult stem cells found in fatty tissue - could one day be used to treat patients with severe wounds and other serious conditions.

8 Jun 2010

Research findings open door to development of new therapies for lymphomas, leukemias

Scripps Research Institute scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers.

8 Jun 2010

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Keryx Biopharmaceuticals, Inc. today announced that Phase 1 data of KRX-0401 (perifosine) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, IL.

7 Jun 2010

Microscopic image sensor to speed up detection of tumors

To diagnose cancer reliably, doctors usually conduct a biopsy including tissue ana-lysis - which is a time-consuming process. A microscopic image sensor, fitted in an endoscope, is being developed for in vivo cancer diagnosis, to speed up the detection of tumors.

7 Jun 2010

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.

7 Jun 2010

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Focusing on helping clinicians improve experiences for their patients, GE Healthcare is highlighting an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine, June 5-9, in Salt Lake City.

7 Jun 2010

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).

7 Jun 2010

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that two scientific abstracts on the activity of tranilast against key components of gout - high serum uric acid levels and monosodium urate crystal-induced inflammation - have been accepted for The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology, to be held in Rome, Italy, June 16-19, 2010.

4 Jun 2010

YM BioSciences raises $3.2M through non-brokered private placement of common shares

YM BioSciences Inc., announced today that it has raised approximately US$3.2 million through a non-brokered private placement of 2,500,000 common shares to be issued at US$1.27. The sale price is at no discount to the closing price of the shares on the NYSE Amex on June 1, 2010.

4 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, announced today that it has completed a $12 million Series A financing. The round was led by Third Rock Ventures and included Pfizer Venture Investments. Proceeds from the financing will be used to continue advancing Ablexis' proprietary AlivaMab Mouse transgenic mouse platform for the discovery of human therapeutic antibodies.

2 Jun 2010

RepRegen reports 3-month data from study of StronBone bioactive glass with Strontium

RepRegen™, the 'smart biomaterials' company previously known as BioCeramic Therapeutics, announced today that three-month data from an in vivo study of its StronBone™ bioactive glass with Strontium demonstrated that it can generate bone quality in and around defects that appears by analytical tests to be significantly superior to a standard bone void filler in the control defect.

2 Jun 2010

Chakra Biotech Sdn Bhd announces name change to Cerca Insights Sdn Bhd

Chakra Biotech Sdn Bhd today announced its name change to Cerca Insights Sdn Bhd. The name change follows the recent completion of a Series B investment round with Malaysian Life Sciences Capital Fund Ltd and the Malaysian Technology Development Corporation Sdn Bhd.

31 May 2010

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

A group of "color-coded" laboratory mice are providing researchers with a novel way of tracking T-cells, enabling them to visualize and monitor the cellular immune responses of transplanted tissue in real time. The new imaging system is described in the June issue of Nature Medicine, which appears on-line this week.

28 May 2010

Low frequency ultrasound can heal and regenerate body tissues

When we think of ultrasound, it's usually imaging the inside of the body that springs to mind. However, while ultrasound imaging typically requires frequencies that are 50 to 2500 times higher than those human ear can detect, recent increasing evidence indicates that ultrasound at lower frequency can also be used to help certain body tissues to heal and regenerate. Now research that appears in Open Access Journal of Tissue Engineering published by SAGE-Hindawi suggests that ultrasound could also help tissue grafts to survive and thrive following surgery.

28 May 2010

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.

27 May 2010

VisEn Medical announces launch of two new imaging agents at EMIM 2010

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the commercial launch of two new imaging agents -- ProSense® 750 FAST for expanded versatility in imaging cathepsin activity, and Neutrophil Elastase™ 680 FAST, for imaging of inflammatory elastase activity associated with disease progression and therapeutic response. The launch announcements were made at the European Molecular Imaging Meeting (EMIM) 2010 in Warsaw, Poland.

26 May 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois.

25 May 2010

in vivo News and Research

Pharnext closes €4.8-million Series A funding round

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

New technology involving adipose stem cells may one day cure patients with severe wounds: Researchers

Research findings open door to development of new therapies for lymphomas, leukemias

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Microscopic image sensor to speed up detection of tumors

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

YM BioSciences raises $3.2M through non-brokered private placement of common shares

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

RepRegen reports 3-month data from study of StronBone bioactive glass with Strontium

Chakra Biotech Sdn Bhd announces name change to Cerca Insights Sdn Bhd

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

Low frequency ultrasound can heal and regenerate body tissues

Restanza shows greater efficacy against species of Plasmodium that cause malaria

VisEn Medical announces launch of two new imaging agents at EMIM 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News